| Title |
Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, October 2013
|
| DOI | 10.1007/s11899-013-0183-0 |
| Pubmed ID | |
| Authors |
Jordan Schecter, Suzanne Lentzsch |
| Abstract |
Multiple Myeloma (MM) is the second most common hematologic malignancy, with approximately 21,000 new diagnoses each year. The prognosis for MM is variable and depends on several factors. This chapter highlights the clinical and pathological features of multiple myeloma to help define the "high-risk" patient. The authors also review clinical trial data in an effort to delineate the optimal treatment strategy for this group of patients. While more research in this field is needed, the available evidence supports the use of bortezomib as induction therapy and maintenance for high-risk patients with multiple myeloma. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
| Members of the public | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 6% |
| Unknown | 17 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 17% |
| Researcher | 3 | 17% |
| Student > Ph. D. Student | 2 | 11% |
| Professor > Associate Professor | 2 | 11% |
| Student > Doctoral Student | 1 | 6% |
| Other | 4 | 22% |
| Unknown | 3 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 61% |
| Agricultural and Biological Sciences | 2 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 11% |
| Unknown | 3 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2013.
All research outputs
#13,394,135
of 22,727,570 outputs
Outputs from Current Hematologic Malignancy Reports
#226
of 427 outputs
Outputs of similar age
#111,469
of 211,948 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#5
of 5 outputs
Altmetric has tracked 22,727,570 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 427 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 211,948 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.